August 28 - September 1, 2010
Stockholm, Sweden
Findings from the Phase III EINSTEIN-DVT study with Rivaroxaban have been presented during the Hot Line Session at the Annual Meeting of the European Society of Cardiology (ESC) in Stockholm, Sweden on August 31, 2010, 11:00-12:30 CEST.
On this occasion we have held a conference call for investors and analysts.
with
Dr. Kemal Malik, Head of Global Development Bayer Schering Pharma
Dr. Frank Misselwitz, Head Therapeutic Area Cardiovascular and Coagulation, Global Clinical Development
Dr. Alexander Rosar, Head of Investor Relations
Background Information | |
|---|---|
About Xarelto® (rivaroxaban) |
|
About the Rivaroxaban Clinical Trial Program |
|
About the EINSTEIN Clinical Trial Program |
|
About the EINSTEIN-DVT Study |
|
About the RECORD Clinical Trial Program |
|
About the ROCKET AF Study |
|
About the ATLAS ACS Clinical Trial Program |
|
About the MAGELLAN Study |
|
Rivaroxaban Bibliography |
|
About Deep Vein Thrombosis (DVT) |
|
About Venous Thromboembolism (VTE) |
|
About Acute Coronary Syndrome (ACS) |
|
About Stroke Prevention in Atrial Fibrillation |
|
About the History of Anticoagulants |
|
Glossary of Terms |
|
You are leaving the Bayer AG website.
Bayer AG is not responsible for the information on the website to which you are linking.
collect